Site is Being Upgraded

Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via up regulation of its target gene Notch3, 10/February/2018, 7.31 am

Molecular therapy for Stroke:  Omeprazole (brand name: Prilosec and Losec), a drug used in the treatment of stomach and duodenal ulcers, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 10/February/2018, 7.04 am
February 10, 2018
Activation of the PD-1 pathway for Pain therapy: D-3-Hydroxybutyrate (D3HB) increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 10/February/2017, 8.00 pm
February 10, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via up regulation of its target gene Notch3


Significance of the study:  

This study suggests, for the first time, that  COR-M2 (CO (Carbon monoxide) Releasing Molecules-2)by increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “COR-M2 or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2). Together, By treating pulmonary hypertensive patients with Carbon monoxide (CO) or small molecule compounds that release CO, one may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how COR-M2 (CO Releasing Molecules-2) inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of COR-M2 (CO Releasing Molecules-2)

 


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How  COR-M2 (CO (Carbon monoxide) Releasing Molecules-2)  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 7.34 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.